Cargando…
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treat...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101890/ https://www.ncbi.nlm.nih.gov/pubmed/21654875 http://dx.doi.org/10.2147/NDT.S10097 |